共 50 条
- [1] Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple MyelomaBLOOD, 2022, 140 : 4444 - 4446Rodriguez Otero, PaulaJoseph, Nisha S.Kumar, Shaji K.Lee, Hans C.Leleu, XavierManier, SalomonDimopoulos, Meletios A.Victoria Mateos, MariaOriol, AlbertBumma, NareshGong, WeiyingRoy, PourabLorenc, Karen RodriguezKroog, Glenn S.Sarkaria, Shawn M.
- [2] Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human StudyBLOOD, 2022, 140 : 10140 - 10141Bumma, NareshRichter, JoshuaBrayer, JasonZonder, Jeffrey A.Dhodapkar, MadhavShah, Mansi R.Hoffman, James E.Mawad, RayaMaly, Joseph J.Lentzsch, SuzanneSuvannasankha, AttayaRoy, PourabDey, JyotirmoyChokshi, DhrutiBoyapati, AnitaVisich, JennHouvras, YarivLorenc, Karen RodriguezKroog, Glenn S.Jagannath, Sundar
- [3] Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a Phase 1/2 study in patients with relapsed/refractory multiple myelomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S35 - S35Zonder, JeffreyRichter, JoshuaBumma, NareshBrayer, JasonHoffman, James E.Bensinger, William I.Wu, Ka LungXu, LinzhiChokshi, DhrutiBoyapati, AnitaCronier, DamienHouvras, YarivLorenc, Karen RodriguezKroog, Glenn S.Dhodapkar, Madhav V.Lentzsch, SuzanneCooper, DennisJagannath, Sundar
- [4] Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple MyelomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S406 - S407Zonder, Jeffrey A.Richter, JoshuaBumma, NareshBrayer, JasonHoffman, James E.Bensinger, William I.Wu, Ka LungXu, LinzhiChokshi, DhrutiBoyapati, AnitaCronier, DamienHouvras, YarivLorenc, Karen RodriguezKroog, Glenn S.Dhodapkar, Madhav V.Lentzsch, SuzanneCooper, DennisJagannath, Sundar
- [5] Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)BLOOD, 2021, 138Zonder, Jeffrey A.Richter, JoshuaBumma, NareshBrayer, JasonHoffman, James E.Bensinger, William I.Wu, Ka LungXu, LinzhiChokshi, DhrutiBoyapati, AnitaSharma, ManishLorenc, Karen RodriguezKroog, Glenn S.Dhodapkar, Mahdav V.Lentzsch, SuzanneCooper, DennisJagannath, Sundar
- [6] REGN5458, a Bispecific BCMAxCD3 T Cell Engaging Antibody, Demonstrates Robust In Vitro and In Vivo Anti-Tumor Efficacy in Multiple Myeloma Models, Comparable to That of BCMA CAR T CellsBLOOD, 2018, 132Dilillo, David J.Olson, KaraMohrs, KatjaMeagher, T. CraigBray, KevinSineshchekova, OlgaStartz, ThomasRetter, MarcGodin, StephenDelfino, FrankLin, JohnSmith, EricThurston, Olin GavinKirshner, Jessica R.
- [7] Trial in progress: linvoseltamab, a BCMAxCD3 bispecific antibody, in a Phase 1b multi-cohort study of combination regimens for patients with relapsed/refractory multiple myelomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S60 - S60Rodriguez-Otero, PaulaJoseph, NishaKumar, ShajiLeleu, XavierManier, SalomonDimopoulos, MeletiosMateos, Maria-VictoriaOriol, AlbertBumma, NareshGong, WeiyingRoy, PourabLorenc, Karen RodriguezKroog, GlennSarkaria, Shawn
- [8] REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)BLOOD, 2020, 136Madduri, DeepuRosko, AshleyBrayer, JasonZonder, JeffreyBensinger, William I.Li, JingjinXu, LinzhiAdriaens, LieveChokshi, DhrutiZhang, WeijiangBoyapati, AnitaSharma, ManishSeebach, FrankSirulnik, L. AndresWeinreich, David M.Yancopoulos, George D.Dhodapkar, Madhav V.Lentzsch, SuzanneCooper, DennisJagannath, Sundar
- [9] Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple MyelomaBLOOD, 2019, 134Cooper, DennisMadduri, DeepuLentzsch, SuzanneJagannath, SundarLi, JingjinBoyapati, AnitaAdriaens, LieveChokshi, DhrutiZhu, MinLowy, IsraelWeinreich, David M.Yancopoulos, George D.Sharma, ManishKarasarides, MariaSternberg, David
- [10] Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myelomaBLOOD CANCER JOURNAL, 2018, 8Kumar, Shaji K.Buadi, Francis K.LaPlant, BetsyHalvorson, AleseLeung, NelsonKapoor, PrashantDingli, DavidGertz, Morie A.Go, Ronald S.Bergsagel, P. LeifLin, YiDispenzieri, AngelaHwa, Yi LisaFonder, AmieHobbs, MiriamFonseca, RafaelHayman, Suzanne R.Stewart, A. KeithLust, John A.Mikhael, JosephGonsalves, WilsonReeder, CraigSkacel, TomasRajkumar, S. VincentLacy, Martha Q.